Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $214,018.70 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 305,741 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $0.70, for a total value of $214,018.70. Following the completion of the transaction, the director owned 1,273,008 shares in the company, valued at $891,105.60. The trade was a 19.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $43,446.40.
• On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total value of $22,745.16.
• On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $49,824.18.
• On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total value of $9,659.10.
• On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total value of $4,733.40.
• On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total value of $34,533.36.
• On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total value of $42,627.62.
• On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.72, for a total value of $121,148.64.
• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total value of $39,025.71.
• On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.73, for a total value of $69,650.76.

Werewolf Therapeutics Trading Down 7.1%

Shares of NASDAQ HOWL opened at $0.54 on Friday. The stock has a fifty day simple moving average of $0.81 and a two-hundred day simple moving average of $0.82. Werewolf Therapeutics, Inc. has a 1-year low of $0.50 and a 1-year high of $2.38. The firm has a market cap of $26.37 million, a price-to-earnings ratio of -0.44 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.04. Analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Analysts Set New Price Targets

HOWL has been the topic of several recent research reports. Wall Street Zen downgraded Werewolf Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Werewolf Therapeutics currently has a consensus rating of “Hold” and an average price target of $3.75.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors have recently made changes to their positions in HOWL. Regal Investment Advisors LLC lifted its position in shares of Werewolf Therapeutics by 93.3% during the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after acquiring an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. increased its holdings in shares of Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares during the period. Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics in the second quarter worth $48,000. AQR Capital Management LLC bought a new position in shares of Werewolf Therapeutics in the first quarter worth $79,000. Finally, Bridgeway Capital Management LLC increased its holdings in shares of Werewolf Therapeutics by 157.7% in the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares during the period. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.